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Abstract
Waddlia chondrophila, an obligate intracellular bacterium of the
Chlamydiales order, is considered as an agent of bovine
abortion and a likely cause of miscarriage in humans. Its role
in respiratory diseases was questioned after the detection of its
DNA in clinical samples taken from patients suffering from
pneumonia or bronchiolitis. To better define the role of
Waddlia in both miscarriage and pneumonia, a tool allowing
large-scale serological investigations of Waddlia seropositivity is
needed. Therefore, enriched outer membrane proteins of W.
chondrophila were used as antigens to develop a specific ELISA.
After thorough analytical optimization, the ELISA was validated
by comparison with micro-immunofluorescence and it showed a
sensitivity above 85% with 100% specificity. The ELISA was
subsequently applied to human sera to specify the role of W.
chondrophila in pneumonia. Overall, 3.6% of children showed
antibody reactivity against W. chondrophila but no significant
difference was observed between children with and without
pneumonia. Proteomic analyses were then performed using
mass spectrometry, highlighting members of the outer mem-
brane protein family as the dominant proteins. The major
Waddlia putative immunogenic proteins were identified by
immunoblot using positive and negative human sera. The new
ELISA represents an efficient tool with high throughput
applications. Although no association with pneumonia and
Waddlia seropositivity was observed, this ELISA could be used
to specify the role of W. chondrophila in miscarriage and in
other diseases.
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Introduction
Waddlia chondrophila is a Chlamydia-related bacterium belong-
ing to the Waddliaceae family, one of the seven families and
family-level lineages classified within the Chlamydiales order.
The established human pathogens of the Chlamydiaceae family
(Chlamydia trachomatis, C. pneumoniae and C. psittaci) have been
extensively studied, as compared to the other six families of
Chlamydia-related bacteria that remain poorly investigated so
far.
Waddlia chondrophila was originally isolated from bovine
foetuses [1, 2] and since then, several serological studies
have supported an association with bovine abortion [3, 4].
Considering human pathogenicity, a recent serological study
on pregnant women suggested that W. chondrophila sero-
positivity correlated with miscarriage [5]. Moreover, one
case of W. chondrophila-associated miscarriage was docu-
mented by immunohistochemistry, specific PCR and
micro-immunofluorescence (MIF) [6]. These observations
are of major importance, since human miscarriage has no
aetiology in about 50% of cases and since 32% of women
with miscarriage exhibited anti-Waddlia antibody reactivity
[5]. In addition, W. chondrophila may also represent a novel
agent of respiratory tract infection since its DNA was
detected by PCR in (1) 9.4% of nasopharyngeal aspirates
taken from children with bronchiolitis and tested negative
for the respiratory syncytial virus [7], and (2) the sputum
sample of a patient with pneumonia [8].
Waddlia chondrophila, like the other members of the
Chlamydiales order, is a strict intracellular bacterium that
exhibits two developmental stages. The extracellular infectious
elementary body (EB) infects host cells and then differentiates
ª 2014 The Authors. New Microbes and New Infections published by John Wiley & Sons Ltd on behalf of the European Society of Clinical Microbiology and Infectious Disease.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and
distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
NEW TECHNOLOGIES FOR INFECTIOUS AND TROPICAL DISEASES 10.1002/2052-2975.26
into a replicative form called the reticulate body. The obligate
intracellular lifestyle of the members of the Chlamydiales
order has rendered their detection by culture particularly
tedious. The diagnosis of these bacterial infections is thus now
mainly performed using molecular tools and/or serology. The
current reference standard method in chlamydial serology
remains MIF, based on whole-cell bacteria, despite its lower
sensitivity compared to ELISAs [9, 10]. Moreover, MIF is a
time-consuming and fastidious technique, in which there is
almost no automation and which is largely dependent on a
reader’s objectivity. Conversely, although ELISA is more
difficult to implement, it has the advantages of being easily
automated, providing quantitative results and allowing large-s-
cale screenings of samples.
The recently published genome of W. chondrophila [11]
was previously used for downstream proteomic investiga-
tions: 13 different immunogenic proteins were previously
described [12]. However, no membrane proteins were
identified in this study although membrane proteins are
known to often be immunogenic. The method used to
prepare whole-cell proteins with urea and centrifugation
might have eliminated most outer membrane proteins,
which are often insoluble cross-linked proteins [13].
Furthermore, when testing human sera known to exhibit
anti-Waddlia reactivity, their reactivity against each of the 13
individual proteins identified by Kebbi-Beghdadi et al. [12]
was heterogeneous, with only a third of sera reacting
against some of these 13 proteins. Finally, two candidates
were identified as putative immunogenic proteins for the
development of an ELISA. However, these two proteins
exhibited low specificity in additional tests recently per-
formed using animal sera.
Thus, in the present work, outer membrane proteins
known to be insoluble in the detergent sarkosyl were
enriched from elementary bodies of Waddlia and used as
antigens in a new ELISA. After initial common troubleshoot-
ing steps, the new ELISA was validated on sera previously
screened by the reference standard MIF for ‘waddlial’
reactivity. Then, in order to specify the potential role of
W. chondrophila in respiratory infections, the ELISA was
applied to sera taken from 364 children with (n = 189) or
without (n = 175) pneumonia.
Additional work was conducted using mass spectrometry
(MS) to further characterize the enriched fraction of the
outer membrane proteins of Waddlia. Finally, acrylamide
two-dimensional (2D) gels coupled with immunoblots incu-
bated with Waddlia-positive and -negative human sera were
performed to identify major Waddlia-specific immunogenic
proteins.
Material and Methods
Ethics statement
The obtention of children’s sera was done as part of a larger
study investigating various agents of lower respiratory tract
infection (see below: ‘Human sera’). This study was approved
by the Geneva University Hospital Ethics Committee (No. CE
04-199). Written consent was systematically obtained from
children’s parents.
Human sera
The ELISA test was applied to 364 serum samples collected
between 2008 and 2010 at the University Hospital of Geneva
from children with (n = 189) and without (n = 175) pneumo-
nia and aged between 0 and 17 years. The children with
pneumonia were sampled at day 0 (serum A) and day 14
(serum B) during the course of their disease. The diagnosis of
pneumonia was based on the following criteria: fever (tem-
perature >38°C), cough, infiltrate or consolidation on lung
X-ray, dyspnoea or tachypnoea. All patients were systemat-
ically tested for respiratory viruses (influenza virus A and B;
parainfluenza virus 1, 2 and 3; human metapneumovirus A and
B; human respiratory syncitial virus A and B; adenovirus A, B
and C; enterovirus A, B, C and D; rhinovirus A and B;
coronavirus HKU1, OC43, 229E and NL63; and H1N1) as well
as for Streptococcus pneumoniae, Mycoplasma pneumoniae,
Legionella pneumophila and Chlamydia pneumoniae. The valida-
tion of the ELISA was also performed on 95 serum samples
collected at the Recurrent Miscarriage Clinic of St Mary’s
Hospital, London. These samples were previously tested by
MIF on heat-inactivated W. chondrophila and observed at a
magnification of 9400. Chlamydia trachomatis seropositivity
was determined using commercial tests [9]. These sera were
re-tested in this study using a modified MIF protocol (see
below) and by ELISA.
Specificity of the ELISA
The specificity of the ELISA was evaluated using sera from mice
or rabbits (Eurogentec, Seraing, Belgium) immunized with
heat-inactivated Waddlia chondrophila strain WSU 86-1044,
Parachlamydia acanthamoebae strain Hall’s coccus, Criblamydia
sequanensis strain CRIB 18, Estrella lausannensis strain CRIB 30,
Simkania negevensis ATCC VR 1471 and Protochlamydia
amoebophila strain UWE25.
Micro-immunofluorescence assay
The MIF performed in this work used formalin-inactivated
bacteria. The protocol below was based on a protocol
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published already [5] and modified in this work to enhance
sensitivity and specificity. EBs of Waddlia chondrophila strain
WSU 86-1044 were purified as described before [11]. Briefly,
from a co-culture with the amoeba Acanthamoeba castellanii
ATCC 30010, EBs were harvested by centrifugation and
purified sequentially with sucrose and gastrografin gradients.
Purified EBs were inactivated with 0.3% formalin for 1 h at
room temperature (RT) and washed three times with phos-
phate-buffered saline (PBS). Bacteria were then spotted on
glass slides (previously dried clean with ethanol) and air-dried
overnight at RT. Bacterial spots were saturated with a blocking
solution (BS) consisting of PBS with 1% bovine serum albumin
(BSA) (Promega, D€ubendorf, Switzerland) for 1 h 30 min at
RT and then washed (in three steps: with PBS 0.03%
Tween-20, with PBS, and then with distilled water). Sera
diluted 1:32 in BS were applied on the bacterial spots for 1 h at
RT. After a washing step, spots were immediately incubated
for 1 h with a goat anti human IgH-fluorescein conjugated
antibody (Fluoline H; BioMerieux, Marcy l’Etoile, France)
diluted 1:400 in BS and 300 nM of 4′,6-diamidino-2-phenylin-
dole, DAPI (Invitrogen, Basel, Switzerland). Glass slides were
washed and mounted in Mowiol. Fluorescence was observed
with an epifluorescence microscope (Axioplan 2; Zeiss,
Feldbach, Switzerland) at a magnification of 91000, by two
different readers. Each serum was tested in duplicate and each
replicate received a score of ‘0’ if negative, ‘0.5’ if doubtful or
‘1’ if positive, by each reader. All sera had a total score
between 0 and 4. Scores from 0 to 0.5 were considered
negative, 1 to 1.5 were doubtful low, 2 to 3 doubtful high and
3.5 to 4 were considered positive.
Enrichment of W. chondrophila outer membrane proteins
Outer membrane proteins were isolated from purified EBs of
W. chondrophila, obtained as described above. EBs were
centrifuged and resuspended in 1 mL of PBS with 2%
N-lauroylsarcosine sodium salt solution (sarkosyl) (Sigma,
Buchs, Switzerland) and 1.5 mM EDTA and incubated 1 h at
37°C. Lysed bacteria were then ultracentrifuged for 1 h at
100 000g at 4°C. The procedure was repeated by resuspend-
ing the pellet in sarkosyl with a total of three ultracentrifu-
gations. Before the ultimate ultracentrifugation, the
resuspended pellet was sonicated for 5 min in a water bath.
At the end, the pellet was resuspended with 50 mM
dithiothreitol (DTT; Applichem, Baden-D€attwil, Switzerland)
and 0.2 M urea (Sigma, Buchs, Switzerland) and treated with
10 U DNAse I (RNAse free) (New England Biolabs, BioCon-
cept, Allschwil, Switzerland) at 40°C for 3 h. After a final
centrifugation (3 min at 13 000g), the supernatant containing
outer membrane proteins was stored at 20°C. Proteins
were quantified using nigrosin staining. Briefly, the proteins
were spotted on Whatman paper, allowed to air-dry and then
stained for 5 min with nigrosin (Sigma, Buchs, Switzerland) in
2.5% acetic acid and washed with 5% acetic acid. Quantification
was performed using a standard curve of bovine serum
albumin (Biorad, Reinach BL, Switzerland) and analysis by
Image J software (http://rsb.info.nih.gov/ij/). In the present
article, the outer membrane proteins are also called sarkosyl
insoluble proteins. Three different preparations of enriched
proteins were used in this work.
ELISA assay
ELISA assays were performed in 96-well certified maxisorp
microplates (Nunc, VWR International, Dietikon, Switzerland),
where 1.5 lg/mL of outer membrane proteins were coated
(100 lL) in sodium carbonate and bicarbonate buffer pH 9.6,
overnight at 4°C. Microplates were washed (once with PBS
and once with PBS 0.05% Tween-20). Wells were saturated
with 100 lL of BS consisting of PBS with 5% BSA (Promega)
and 0.5% gelatin (Merk, Zug, Switzerland) for 2 h at RT. After a
washing step, wells were incubated with sera (50 lL) diluted in
BS for 1 h at RT. Human sera were diluted 1:128, mice and
rabbits sera were diluted two-fold from 1:256 to 1:2048 and
from 1:8000 to 1:32 000, respectively. Wells were then
washed and incubated for 45 min at RT with a horseradish
peroxidase-conjugated secondary antibody diluted in BS. The
goat anti-human IgH (A + G + M) (Millipore, Zug, Switzer-
land) was diluted 1:60 000, the goat anti-mouse IgG (Bio-Rad,
Reinach, Switzerland) diluted 1:1000 and the goat anti-rabbit
IgG (Abcam, Cambridge, UK) diluted 1:2000. Wells were
washed as before and a final wash of PBS was added. Finally
1 mg/mL o-phenylenediamine dihydrochloride (OPD) (Sigma,
Buchs, Switzerland) with 0.03% H2O2 in 0.1 M citrate buffer,
pH 5 was added. The reaction was stopped with H2SO4 3 M
(50 lL). Optical density (OD) was measured on an ELISA
Multiskan ascent reader (Thermo Scientific, Zurich, Switzer-
land) at 492 nm against 650 nm as a reference. Each serum
sample was tested in three independent experiments. Sera
from British women (tested in MIF) were systematically added
in each experiment to calculate receiver operating curves
(ROCs) and to define a grey zone: sera above, inside and
below this zone were considered positive, doubtful or
negative, respectively. When the sera from children were
tested by the W. chondrophila specific ELISA, the patients were
considered positive when seropositivity was observed in the
three independent experiments.
MS analysis of the enriched fraction of outer membrane
proteins
Sarkosyl insoluble proteins were prepared as described above.
About 200 lg of proteins were analysed by MS. Proteins were
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first loaded on a 12% acrylamide gel and then stained with
Coomassie blue. Then, the gel was excised from the loading
point to the bottom into five equal bands that were
subsequently digested with trypsin (Promega) [14, 15]. The
derivated peptides were analysed by LC-MS/MS on a hybrid
linear trap LTQ-Orbitrap XL mass spectrometer (Thermo
Fisher Scientific, Zu¨rich, Switzerland) coupled to a nanocap-
illary HPLC with a C18 reversed-phase column. Analysis of the
raw data was performed by Mascot Distiller 2.3.2 and Mascot
2.3 (Matrix Science, London, UK) against the Uniprot database
(http://www.uniprot.org) restricted to Waddlia chondrophila
WSU 86-1044 and against a custom-built database containing
the sequence of common contaminants (enzymes, keratins).
Trypsin (cleavage at K, R, not before P) was used as the
enzyme definition. Mascot was searched with a fragment ion
mass tolerance of 0.50 Da and a parent ion tolerance of
10 ppm. The iodoacetamide derivative of cysteine was spec-
ified in Mascot as a fixed modification. N-terminal acetylation
of protein, deamidation of asparagine and glutamine and
oxidation of methionine were specified as variable modifica-
tions. The software Scaffold version 3 was then used to
validate MS/MS based peptide and protein identifications and
to perform dataset alignment. Peptide identifications were
accepted if they could be established at greater than 90.0%
probability as specified by the Peptide Prophet algorithm [16].
Protein identifications were accepted if they could be estab-
lished at greater than 95.0% probability by the Protein Prophet
algorithm [17] and contained at least two identified peptides.
Proteins that contained similar peptides and could not be
differentiated based on MS/MS analysis alone were grouped to
satisfy the principles of parsimony. The relative abundance of
the proteins identified was estimated using the calculation of
an exponentially modified protein abundance index (emPAI)
[18]. Details of this index can be found at the website http://
www.matrixscience.com/help/quant_empai_help.html. This
index was based on the theorical and observed number of
unique peptides after trypsin digestion of the proteins:
emPAI = (10^(Nobserved/Nobservable)  1, with N for the num-
ber of peptide.
Preparation of 2D gels
Sarkosyl insoluble proteins were prepared as described above
but the final pellet was resuspended in 5 M urea, 2 M thiourea,
35 mM Tris, 4% CHAPS, 0.5% Triton X-100, 1% ASB-14 and
50 mM DTT. Proteins (100 and 150 lg) were then desalted,
concentrated and resuspended in a DeStreak rehydration
solution with 0.5% IPG buffer pH3-11 NL. Rehydration was
performed overnight on immobiline DryStrip pH3-11 NL (GE
Lifesciences, Glattbrugg, Switzerland). The first dimension of
2D electrophoresis was performed at 20°C on an Ettan
IPGphor 3 IEF System (GE Lifesciences) with the following
program: 30 min at 200 V, 90 min at 2000 V, 60 min at
3500 V and 60 min at 3500 V (current 2 mA total, power
5 W total and 7500 Vh). After the run, the strips were
equilibrated for 15 min with 6 M urea, 2% SDS, 0.375 M
Tris-HCl pH 8.8, 20% glycerol and 130 mM DTT and then
15 min in urea, 2% SDS, 0.375 M Tris-HCl pH 8.8, 20%
glycerol and 135 mM iodoacetamide. Then, the second
dimension was done on a Mini Protean-3 Vertical Electropho-
resis Unit (Bio-Rad, Reinach BL, Switzerland) with 13%
acrylamide gels for 90 min at 140 V, using a running buffer
of 0.3025% Tris, 1.44% glycine and 0.1% SDS. Seven acrylamide
gels were prepared; one was stained with Coomassie blue
using the Protoblue Safe Colloidal Commassie G-250
(National Diagnostics, Basel, Switzerland) and the six other
gels were transferred on nitrocellulose membranes.
Immunoblot analysis
The six nitrocellulose 2D-gel membranes were first blocked
for 1 day at RT in 5% non-fat dry-milk in 50 mM Tris, 150 mM
NaCl and 0.2% Tween-20 (TBST). After a short washing step
in TBST 0.5% non-fat dry-milk, immunoblots were incubated
overnight at 4°C, with human sera (three Waddlia positive and
three Waddlia negative sera from British women [5]) diluted
1:10 in TBST 0.5% non-fat dry-milk. After three washes of
10 min with TBST 0.5% non-fat dry-milk, the blots were
incubated with a horseradish peroxidase-conjugated goat
anti-human IgH (A + G + M) (Millipore, 1:120 000) for 1 h
at RT. Three washes of TBST were done prior to visualization
with a chemoluminescent solution of luminal, p-coumaric acid,
Tris 1.5 mM pH 8.5 and H2O2. Images of the six immunoblots
were superimposed on the Coomassie gel image using the
photoshop software version 3 and reactive spots were
selected.
Analysis of major immunogenic proteins by MS
For analysis of 2D gels, spots were picked and analysed by MS
as described above.
Results
Specificity of the ELISA with antisera from immunized
rabbits and mice
Twofold dilutions of sera from mice or rabbits immunized with
six different Chlamydia-related bacteria belonging to four
distinct families have been tested (1/256 to 1/2048 for mice
sera and 1/8000 to 1/64 000 for rabbits sera). Waddlia
chondrophila immunized mice or rabbits gave a strong signal
in ELISA (OD492nm 3 for the highest concentration of the
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serum, as shown in Fig. 1a and b). Sera from animals
immunized with the five other Chlamydia-related bacteria did
not exhibit significant cross-reactivity with proteins from
Waddlia. Only the specific S. negevensis mice anti-sera showed
some cross-reaction whereas the homologous rabbit anti-sera
did not. As expected, all pre-immune sera did not display
anti-Waddlia reactivity.
Comparison of two protocols of MIF and validation of the
ELISA
MIF is the reference standard in chlamydial serology. In this
work, two different protocols of MIF were compared. A MIF
protocol based on heat-inactivated bacteria (hereafter called
‘h-MIF’) and read at a magnification of 9400 was compared to
a MIF protocol using formalin-inactivated bacteria (hereafter
called ‘f-MIF’) read at a magnification of 91000. In a previous
study, 95 samples of serum taken from British women tested
with the h-MIF [5], were tested in this work by the f-MIF. The
number of positive, negative or doubtful serology for W.
chondrophila is summarized in Table 1. The number of doubtful
results was 1.4 times higher with the h-MIF compared with the
f-MIF. When comparing results of the f-MIF with the h-MIF, the
overall correlation was 39% considering positive, negative and
doubtful sera. Fig. S1 illustrates the validation of the ELISA
using both MIFs as a reference standard. In Fig. S1a, sera from
British women which tested positive and negative with both
MIFs (n = 32) were analysed by the ELISA. The results
indicated that the ELISA was able to discriminate between
positive and negative sera. In order to evaluate the efficiency of
the ELISA, ROCs were calculated using the OD492nm values
obtained with positive and negative sera according to the
h-MIF or the f-MIF (Fig. S1b). The mean area under the ROC
for h-MIF or f-MIF (Fig. S1b) was 0.968  0.012 and
0.967  0.010, respectively. These values close to 1 showed
the high performance of the ELISA. The statistical analysis using
the unpaired t test demonstrated that MIF-based negative and
positive human sera were significantly discriminated by the
ELISA (p value <0.0001 for both MIFs). Considering OD492nm
values that gave 100% specificity, the ROCs proposed cut-offs
corresponding to the highest sensitivity. Overall, five and eight
independent experiments of ROC were performed for h-MIF
and f-MIF, respectively. The calculated OD492nm cut-off for the
ELISA based on the h-MIF gave a mean sensitivity of
71.7  11.3%. For the ELISA based on the f-MIF, the optimal
cut-off gave a mean sensitivity of 86.6  3.0%. For each
experiment, the optimal determined cut-offs were applied on
all the 95 sera tested with the ELISA and each serum was
classified according to the serological results obtained with the
h-MIF (Fig. S1c) or with the f-MIF (Fig. 2). In the ELISA based
on the f-MIF, mean OD492nm values increased when the score
of the MIF increased. With 100% specificity for the ELISA
based on both MIF, the sensitivity of the ELISA was higher
when based on the f-MIF (Fig. S1b). The f-MIF was thus chosen
as the best reference standard to calculate OD492nm cut-offs
for the ELISA in the subsequent experiments. All ‘doubtful low’
sera taken from British women were also used to define a high
threshold. Thus, the calculated cut-off using the ROC and the
FIG. 1. Cross-reactivity of theWaddlia chondrophila-specific ELISA. Anti-sera from rabbits (a) or mice (b) immunized with Chlamydia-related bacteria
belonging to four different families were used. Cross-reactivity against Protochlamydia amoebophila was tested only with rabbit anti-sera whereas
cross-reactivity against Estrella lausannensis and Criblamydia sequanensis was tested only with mouse anti-sera. Note the limited cross-reactivity with
other species (open symbols) and the absence of reactivity of the pre-immune sera (in grey).
TABLE 1. Comparison of two protocols of the micro-immu-
nofluorescence (MIF) using heat (h-MIF) or formalin (f-MIF)
inactivated bacteria applied on 95 sera from British women
h-MIF f-MIF
Identical
result in
both MIF
Seropositivity 29 57 24
Seronegativity 33 14 8
Doubtful serology 33 24 5
Total 95 95 37
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high threshold determine a grey zone (Fig. S1c and Fig. 2). The
sera with OD492nm values above, inside or below this grey
zone were then considered in the next experiments as
positive, doubtful or negative, respectively.
Application of the ELISA to sera from children with or
without pneumonia
Sera from children with (n = 189) or without (n = 175)
pneumonia were tested with the new ELISA (Fig. 3). Sera from
British women were included in each experiment as internal
controls and in order to calculate a ROC and to define a grey
zone. Results from three independent experiments are
summarized in Table 2. Among the children with or without
pneumonia, Waddlia seropositivity above the grey zone (i.e.
positive) was observed in seven (3.7%) and six (3.4%) patients,
respectively. The analysis of the sera at day 14 for children
with pneumonia showed that one patient exhibited a sero-
conversion. The clinical characteristics of the 13 positive
patients are indicated in Table S1. The aetiology of the
pneumonia was identified for two patients (Streptococcus
pneumoniae and rhinovirus A, respectively) whereas the other
five positive patients remained with unknown aetiology (Table
S1). Furthermore, 17.5% and 19.4% of the patients with and
without pneumonia, respectively, exhibited antibody reactivity
in the grey zone corresponding to a doubtful seropositivity.
Overall, these results indicated no significant difference
between ill and control children for high positivity (odds ratio
FIG. 2. Validation of the ELISA on 95 sera from British women using
the reference standard formalin micro-immunofluorescence (f-MIF).
OD492nm values of 95 sera from British women tested by ELISA and
classified according to the results of the f-MIF. The dashed lines define
a grey zone: a low threshold calculated by the receiver operating curve
(ROC) to have 100% specificity and the highest sensitivity and a high
threshold above OD492nm values corresponding to ‘doubtful low’ sera.
Sera with OD492nm values above the grey zone are considered positive.
The bars indicate the mean for each group. One representative
experiment is shown here.
FIG. 3. Application of the ELISA to sera from children with (189) and
without (175) pneumonia. The dashed lines correspond to the grey
zone determined by the receiver operating curve (ROC) (low line) and
the doubtful low sera (high line). One representative experiment is
shown here.
TABLE 2. ELISA applied to sera from children with (n = 189) and without (n = 175) pneumonia
No pneumonia
Pneumonia
Only at day 0 Only at day 14 At days 0 and 14 Total
Negative 135 (77.1%) — — 149 (78.8%) 149 (78.8%)
Grey zone 34 (19.4%) 7 (3.7%) 2 (1.1%) 24 (12.7%) 33 (17.5%)
Positive 6 (3.4%) 3 (1.6%) 1 (0.5%) 3 (1.6%) 7 (3.7%)
Total 175 — — — 189
The results were obtained from three independent experiments.
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[OR] = 1.08 with a confidence interval [CI] of 0.36–3.28) as
well as for low or doubtful seropositivity (OR = 0.91 and CI of
0.55–1.49).
Identification of sarkosyl insoluble proteins ofW. chondrophila
by MS
Using MS analysis on the enriched fraction of sarkosyl insoluble
proteins, 617 proteins were identified (Table S2). Among these
proteins, 328 were identified with more than four matched
spectra providing sufficient confidence for subsequent analysis.
The relative abundance of the proteins was roughly estimated
based on the theoretical and observed number of peptide
generated after trypsin digestion of each protein and the 40
most abundant proteins are represented in Fig. 4. Among
these 40 most abundant proteins, 11 corresponded to
membrane proteins or proteins associated to the membrane:
proteins of the outer membrane protein (OMP) family
(OmpA11, A2, A3, A7, A10, A1, A4), proteins with predicted
transmembrane domains such as the three putative membrane
proteins wcw_1100, wcw_1236 and wcw_1644, and the
putative long-chain fatty acid transport protein FadL with a
predicted peptide signal. Three other proteins identified in the
present work were previously shown to be immunogenic
proteins [12] using a different approach: the elongation factors
FusA and Tuf and, by homology, GroEL2. The putative needle
chaperone SctG was also detected and is associated with the
type III secretion system inserted in the bacterial membrane.
Polymerases (RpoA and B) and ribosomal proteins as well as
proteins of metabolic pathways were also recovered. Finally,
six other proteins are putative uncharacterized proteins.
Considering the relative abundance of each identified
protein, five proteins appeared to be predominant: OmpA11,
OmpA2, OmpA3, as well as the putative uncharacterized
proteins wcw_1930 and wcw_11100 (Fig. 4).
Identification of the major immunogenic proteins by 2D gels
Sera from children who tested Waddlia positive and negative
by ELISA were selected. Immunoblots derived from acrylamide
2D gels used to separate the enriched outer membrane
proteins were incubated with these human sera. It allowed the
FIG. 4. Sarkosyl insoluble proteins ofWaddlia chondrophila identified by mass spectrometry. The 40 most estimated abundant proteins are indicated
here. The calculated relative abundance is indicated on the x-axis and illustrates the proportion of each protein in the sarkosyl insoluble protein
fraction. Proteins in grey correspond to protein with unidentified function according to the UNIPROT database. The star indicates the proteins with
a putative signal peptide in the sequence, ‘Tmd’ corresponds to proteins with a transmembrane domain and ‘Im’ indicates proteins of W. chondrophila
previously shown to be immunogenic [12].
ª 2014 The Authors. New Microbes and New Infections published by John Wiley & Sons Ltd on behalf of the European Society of Clinical Microbiology and Infectious Disease., NMNI, 2, 13–24
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identification of 21 spots (Fig. 5 and Table 3), among which, 13
were analysed by MS: six spots were specifically recognized by
Waddlia-positive human sera (at least by two Waddlia-positive
human sera and by zero or one Waddlia-negative serum) and
seven spots were recognized by both Waddlia-positive and
-negative human sera (at least by two Waddlia-positive human
sera and at least by two Waddlia-negative sera) (Table 3). All
proteins identified by MS are indicated in Table S3. In each
spot, several proteins were identified. Identified proteins
present in the six spots recognized only by the Wadd-
lia-positive sera were selected (Table 4). Overall, 25 putative
immunogenic proteins specific of the Waddlia-positive human
sera were identified among which 11 corresponded to putative
uncharacterized proteins. Based on their absence of low amino
acid sequence identity (identity <45%) with other proteins of
Chlamydiales bacteria (Table 4), eight proteins (marked bold)
unique to Waddlia chondrophila were identified as putative
optimal antigens.
Among the estimated major proteins present in the sarkosyl
insoluble fraction, some proteins were also identified in these
immuno-positive spots: OmpA11, OmpA2, wcw_1930,
OmpA3, GroEL2 and wcw_1100. The Omp proteins and
GroEL2 were identified in spots recognized by both Wadd-
lia-negative and -positive sera and were thus excluded.
Alternatively, the putative uncharacterized proteins
wcw_1100 and wcw_1930 present in the major proteins
identified in the enriched fraction of sarkosyl insoluble
proteins were also identified as proteins unique to Waddlia
using the 2D-gel approach.
Discussion
Waddlia chondrophila is now emerging as a human pathogen. In
order to specify the pathogenic role of this bacterium, tools
allowing large-scale screenings are needed. As serology is one
key approach for diagnosing infections due to such strictly
intracellular bacteria, the development for an ELISA specific of
Waddlia chondrophila was warranted. Commercial chlamydial
ELISA assays or anti-Chlamydia vaccines often use recombinant
membrane proteins such as the major OMP (MOMP) or the
outer membrane complex protein B (OmcB) with good
reliability [19, 20]. The cell wall of Chlamydia species is
organized in a complex of disulfide cross-linked proteins
whose major components are the MOMP, OmcA and B
providing rigidity to the bacterial membrane [13, 21]. The
genome of W. chondrophila did not reveal any MOMPs but
instead 11 cysteine-rich outer membrane proteins (Omp)
[11]. A potential Omc family with OmcA and B and a putative
polymorphic membrane protein (Pmp) were also identified.
Cross-linked chlamydial outer membrane proteins were
already documented as being insoluble in the detergent
sarkosyl [21] as well as being highly immunogenic [22–26].
FIG. 5. Two-dimensional (2D) gel of enriched outer membrane
proteins from Waddlia chondrophila. The gel is stained with Coomassie
blue. After transfer of the 2D gels on nitrocellulose membranes,
western blots were performed with human sera previously tested
Waddlia negative or positive by the new ELISA. The reactive spots
were selected and are numbered here. The reactive spots recognized
by Waddlia positive human sera only are indicated by red rectangles.
TABLE 3. Results of the western blots performed with human sera previously determined as negative or positive by
Waddlia-specific ELISA
Waddlia
seropositivity
Spots no.
1 2 3 4 5 6 7 8 9 10 11 12 15 16 17 18 19 20 21 22 23
Serum 1 Negative +         + +   + +   + +  
Serum 2 + +   + +   + + +     +  +   
Serum 3 + + +   +   +      +     + 
Serum 4 Positive + + + + + +   + + +  + +  +    + 
Serum 5 + + + + + + + + + + +   + + + +   + 
Serum 6 + +   + +   + + +   + + + + +  + +
The reactivity of the sera toward 21 spots of proteins is indicated here. Signal intensity in western blot: (+) positive, () doubtful, and () negative. The spots in bold were analysed
by mass spectrometry.
ª 2014 The Authors. New Microbes and New Infections published by John Wiley & Sons Ltd on behalf of the European Society of Clinical Microbiology and Infectious Disease., NMNI, 2, 13–24
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Indeed, the outer membrane proteins of Waddlia represented
good antigen candidates for the development of serological
tests. Therefore, the elementary bodies of Waddlia were used
to prepare an enrichment of outer membrane proteins. These
proteins were then coated as antigens in the present ELISA,
which showed high responses with homologous mice and
rabbits anti-sera as well as the absence of significant
cross-reactivity with sera specific of other members of the
Chlamydiales order. No animal serum reactive against the
more phylogenetically distant members of the Chlamydiaceae
family was tested in this work. However, no cross-reactivity
was observed for the closest relatives of W. chondrophila.
Moreover, C. trachomatis positive Waddlia negative human sera
from British women (n = 10) were negative with the new
ELISA, indicating that Chlamydiaceae-specific animal sera will
unlikely exhibit cross-reactivity with Waddlia-enriched outer
membrane protein fractions used in this ELISA. Furthermore,
dominant outer membrane proteins of Waddlia (i.e. Omp
proteins) showed no homology with members of the
Chlamydiaceae family.
Despite numerous weaknesses, MIF remains the reference
standard in chlamydial serology. In this work, when comparing
two different protocols of MIF (using heat- and formalin-
inactivated bacteria; h-MIF and f-MIF, respectively) the corre-
lation was 39%, revealing a weak robustness of this technique.
The limit of the MIF was already highlighted for C. trachomatis
serology when comparing a commercial MIF with four
additional commercial serological tests [9]. Nevertheless, no
alternative method could be used as a ‘reference standard’ to
validate the new ELISA. The correlation between the MIF and
the ELISA, illustrated by the ROCs based on positive and
negative sera, was excellent (area under the curve >0.96). The
MIF based on formalin-inactivated bacteria and observation of
the sample at a magnification of 91000 demonstrated an
enhanced sensitivity of the MIF method. Indeed, the number of
detected seropositive sera from British women was higher and
the number of doubtful results reduced with the f-MIF
compared to the h-MIF. The new ELISA was validated using
serological results from British women tested previously by
h-MIF and in this work by f-MIF. The sensitivity of the ELISA was
higher when correlated with the results of the f-MIF than with
the h-MIF (86.6% vs. 71.7%), indicating that the f-MIF is an
optimization of the MIF protocol. The formalin inactivation may
better preserve the integrity of bacterial membrane structures
and epitopes compared to heat inactivation. This latter method
likely significantly damaged the bacterial membrane, exposing
to the surface intracellular epitopes from numerous conserved
proteins which may increase the number of false positive or
doubtful results. In addition, in the f-MIF protocol, fluorescence
was observed at a magnification of 91000, which enabled a
better distinction between the fluorescence of stained bacteria
(W. chondrophila) from background fluorescence or from
non-specific staining, a distinction which was not possible at
the magnification 9400 used in the h-MIF.
Then, the role ofW. chondrophila in respiratory infections was
investigated using sera from children with and without pneu-
monia, showing seropositivity in 3.7% and 3.4% of the patients,
respectively. No significant association was observed between
Waddlia seropositivity and pneumonia. Previous serological
studies on Waddlia seropositivity were conducted in healthy
adults [27] or inwomenwith pregnancy issues [5] where, among
control groups, 13.7% and 7.1% of patients exhibited positive
titres of total Ig ≥64, respectively. These higher prevalences
compared to our present study may be explained by the lower
dilution of the sera, the older age of the patients and the
different methods used in these previous studies.
The analysis of the enriched fraction of outer membrane
proteins of W. chondrophila by MS enabled their identification.
The most estimated abundant proteins corresponded to
membrane proteins: proteins of the Omp family and proteins
with predicted transmembrane domains and/or peptide signals.
Interestingly, among the 11 cysteine-rich OMP proteins, seven
were identified among the 40 most dominant proteins within
the sarkosyl insoluble fraction enriched from elementary
bodies. Since the protein preparation was performed using
the detergent sarkosyl, the fraction was enriched in membrane
proteins and it was expected to find Omp proteins as the
major constituents.
A previous study identified 13 immunogenic proteins of W.
chondrophila [12] of which 12 were also identified in this work
(Table S2). Some of these proteins were previously proven to
give a serological response in 69.2% to 92.3% of patients
seropositive for W. chondrophila such as the chaperon protein
DnaK (Hsp70), the chaperon GroEL1 or the elongation factors
Tu and G [12]. However, these non-membrane and conserved
proteins were enriched by the detergent sarkosyl and may
generate cross-reactions or enhance the background signal as
observed in Fig. S1 for Waddlia-negative sera, for instance.
Therefore, working with outer membrane proteins was
warranted.
The use of enriched outer membrane proteins of Waddlia as
antigens in a specific ELISA proved to be very efficient in this
study. Nevertheless, MS also detected inner membranes and
cytoplasmic proteins, illustrating that the enriched membrane
fraction was contaminated with proteins not located in the
outer membrane. Working with this undefined preparation of
proteins has some disadvantages since it is a complex mixture
that is difficult to quantify and with a relative composition
subjected to variation between different protein preparations.
Thus, the ELISA settings required a new optimization of the
ª 2014 The Authors. New Microbes and New Infections published by John Wiley & Sons Ltd on behalf of the European Society of Clinical Microbiology and Infectious Disease., NMNI, 2, 13–24
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conditions of the ELISA for each protein preparation. Using 2D
gels and immuno-blots with Waddlia-positive and -negative
human sera, the main putative immunogenic proteins unique to
Waddlia were identified and would represent good candidates
as antigens for the future development of a Waddlia-specific
ELISA based on recombinant proteins. As the specificity and
sensitivity of the ELISA is probably based on the immunoge-
nicity of different proteins and not on a single protein, the use
of several candidates should be favoured for future develop-
ment of a Waddlia-specific ELISA. Several putative immuno-
genic proteins such as GroEL, the elongation factors Tu and G
are much conserved bacterial components among bacterial
species. They were recognized by Waddlia-positive and
-negative human sera (Fig. S2) and thus should be avoided.
The eight identified putative uncharacterized proteins, showing
Waddlia-specific immunogenic properties and low or no
identity with other Chlamydiales proteins should be consid-
ered (Table 4) as best putative candidates for the development
of a defined Waddlia-specific ELISA.
The 13 spots characterized by MS were composed of
several proteins highlighting a limited total separation of the
proteins by 2D gel. Some proteins identified in a given spot had
different theorical molecular masses; this phenomenon is likely
due to post-translational modifications.
Consequently, some interesting proteins showing low
identity with other Chlamydiales proteins such as the Omp
were detected in the same spot of conserved proteins like
GroEL. These Omp proteins were thus not selected as
candidates since their corresponding 2D-gel spots were
recognized by both Waddlia-positive and -negative human sera
(Fig. S2). Furthermore, it should be noted that the abundance
of each proteins within a spot was different from the
abundance in the enriched fraction of outer membrane
proteins used in the present ELISA.
In conclusion, this new ELISA was proven to be effective by
comparisons with the reference MIF method and through
validation with animal sera. It demonstrated that Waddlia was
not implicated in pneumonia in this setting. This new tool may
be used to (1) specify the role of this bacterium in miscarriage
where 50% of cases remain with no aetiology, and (2) explore
the role of Waddlia in the pathogenesis of other diseases.
Finally, the proteomic analysis performed in this work con-
ferred some putative antigen candidates that may be used to
optimize this ELISA and other antigens that should be excluded.
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Fig. S1 Validation of the ELISA on 95 sera from British
women using the reference standard MIF. One representative
experiment is shown here. (a) OD492nm values of sera (n = 32)
confirmed as negative or positive using h-MIF and f-MIF. (b)
ROCs of the new ELISA calculated for each MIF: h-MIF (in black)
or f-MIF (in grey). The ROCs were calculated with MIF-based
negative and positive sera. In this experiment, the areas under
the curve for h-MIF and f-MIF were 0.967 and 0.961 and 75.9%
and 84.2% sensitivity, respectively. (c) OD492nm values of 95 sera
from British women tested by ELISA and classified according to
the results of the h-MIF. The dashed lines define a grey zone: a
low threshold calculated by the ROC to have 100% specificity
and the highest sensitivity and a high threshold above OD492nm
values corresponding to ‘doubtful low’ sera. Sera with OD492nm
values above the grey zone are considered positive. The bars
indicate the mean for each group.
Fig. S2 Proteins identified by mass spectrometry from 2D
gel spots of enriched fraction of outer membrane proteins
recognized by both Waddlia-positive and -negative human sera.
The black and white bars correspond to proteins identified in
spots recognized by all human sera and by Waddlia-positive
human sera only, respectively.
Table S1. Characteristics of Waddlia seropositive patients
from Geneva
Table S2. Mass spectrometry analysis of the enriched
outer membrane protein fraction.
Table S3. Identification of immunogenic proteins by mass
spectrometry (spots from the 2D gel)
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